远程缺血适应预防卒中相关性肺炎(RICA-2):多中心、前瞻性、随机、双盲、假对照III期试验方案
RICA-2是一项在中国开展的多中心、随机、双盲、平行对照III期临床试验,计划纳入1650例发病24小时内、NIHSS≥4分的急性缺血性卒中患者,按1:1随机接受远程缺血适应(RIC)或假RIC(袖带压力分别为200 mmHg或60 mmHg),每日两次、连续7天,主要疗效终点为卒中相关性肺炎发生率,并记录安全性。
要点
- RIC组袖带充气压力为200 mmHg,假RIC组为60 mmHg,每日两次、连续7天。
- 主要疗效终点为卒中相关性肺炎发生率,安全性事件将记录并报告。
- 研究旨在验证RIC能否作为预防卒中相关性肺炎的辅助治疗并识别安全性问题。
核心结论
- RIC具有广泛的临床应用前景,可能对卒中相关性肺炎发挥预防作用。
- RICA-2旨在验证RIC治疗能否作为预防卒中相关性肺炎的辅助治疗,并识别安全性问题。
研究设计与样本
- RICA-2是一项在中国开展的多中心、随机、双盲、平行对照III期临床试验。
- 计划纳入1650例年龄≥18岁、急性缺血性卒中症状发作24小时内、美国国立卫生研究院卒中量表评分≥4分的患者。
- 患者按1:1随机分配至RIC组或假RIC组,分别接受袖带充气压力200 mmHg或60 mmHg,每日两次、连续7天。
- 主要疗效终点为卒中相关性肺炎发生率,安全性事件将被记录并报告。
- 试验注册号:ClinicalTrials.gov NCT05982015,注册日期2024年1月22日。
主要发现
- 原文为试验方案,未报告研究结果。
关键数值与推荐
- RIC组袖带充气压力为200 mmHg,假RIC组为60 mmHg。
- 治疗频次为每日两次,连续7天。
- 主要疗效终点为卒中相关性肺炎发生率。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke-associated pneumonia (SAP) is one of the most common complications in acute ischemic stroke (AIS) patients, affecting 8.5% to nearly 30% of cases and significantly impacting both mortality and long-term survival. As it is closely related to worse outcome, exploring effective preventive strategies, such as remote ischemic conditioning (RIC), is essential for reducing SAP incidence and improving patient outcomes. This study aims to compare the efficacy and safety of RIC for preventing SAP in patients with ischemic stroke within 24 h of symptom onset. METHODS AND DESIGN: RICA-2 is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial in China. This study will enroll an estimated 1650 patients aged ≥ 18 years within 24 h after AIS symptom onset, with National Institutes of Health Stroke Scale ⩾ 4. The patients will be randomly assigned to RIC or Sham-RIC (1:1) and will be treated with cuff inflation at 200 mmHg or 60 mmHg, respectively. This procedure will be administered twice daily for seven consecutive days. The primary efficacy endpoint is SAP incidence rate. Safety incidence will be recorded and reported. DISCUSSION: RIC has broad clinical application prospects and may play a preventive role in stroke-related pneumonia. RICA-2 is designed to verify whether RIC treatment can serve as an adjuvant therapy for preventing stroke-associated pneumonia and to identify safety concerns. TRIAL REGISTRATION: ClinicalTrials.gov NCT05982015. Registered on January 22, 2024.
引用
- Jia L, Hou C, Mei Q, et al. Remote ischemic conditioning for the prevention of stroke-associated pneumonia (RICA-2): protocol for a multicenter, prospective, randomized, double-blind, sham-controlled phase III trial. Trials. 2025. PMID: 41102804. doi:10.1186/s13063-025-09140-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。